Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 8. Thalidomide Efficacy—Thalidomide Used As Part of the Pre- or Post- Stem Cell Transplantation Regimen

Study ID

Thalidomide Dose Daily
[Median length of followup]

No. of Patients, Age, Sex, additional MM characteristics


Paraprotein Response


Phase III

*Attal, 2004 (ASH 535)108

Thal dose NS
HDT w/VAD then auto SCT w/ melphalan 200 mg/m2

If no progression at 2 mo after second ASCT, randomized to 3 arms:
A=no maintenance
C=Thal + pamidronate
[26 mo (6-50)]


Inclusion <65 yr
"At diagnosis"
Other pt and MM characteristics NS


Arm A=195
Arm B=190
Arm C=195


Probability of PFS @ 40 mo:
   Arm A=53% (95% CI=37-65)
   Arm B=52% (95% CI=36-68)
   Arm C=70% (95% CI=42-80)

Thal also improves EFS; p<0.01

60% enrolled in Arms A and B received Thal at relapse; OS survival similar in all 3 groups

Barlogie, 2002109

Quality 2/6

Thalidomide as initial phase of Total Therapy program

400 mg
50% randomized to Thal then Intensive Induction w/ VAD (Thal group) or CAD/DCEP (no Thal group) then MEL & transplant; consolidation with DECP (Thal group) or DCEP/CAD (no Thal group); maintenance IFN
[27 mo]

20% >65 yr old

Gender not specified (This is a report on the first 231 randomized of a total 450; patients were randomized to Thal 400 vs. no Thal at the beginning of the Total Therapy II program—these data do not present unblinded outcomes.)


Blinded data—do not know which patients received thal

Overall Response (≥25%)=UTD

m protein reduction:
   @ end of induction
   CR + near CR =30% after second HDT cycle
   CR + near CR=66%
   100% CR=46%
   Near CR=20%

Blinded data—do not know which patients received thal

Overall 3 year estimated


*Barlogie, 2004 (ASH 1483)110


Thalidomide as initial phase of Total Therapy program

Updated report from Barlogie, 2004 (ASH 1483)
[Evaluated at time of treatment failure=med 23 mo from enrollment]

As of 8/4/04, 104 of 668 pts enrolled have been randomized
No Thal=43


Thal salvage response rate =26%

No Thal salvage response rate=51%;  p=0.028

Survival from time of relapse on Total Therapy II was better for those who did not receive Thal maintenance (med 29 vs. 8 mo, p=0.0001)

Hazard ratio for OS post-relapse when Thal maintenance used=2.6; p=0.0006

Lee, 200321

Quality 4/5

50-400 mg within DTPACE regimen
DTPACE x 2 cycles then if >50% response randomized to tandem SCT with high-dose melphalan or 4 more cycles of DTPACE or if <50% SCT; maintenance with Thal 50-200mg and Dex 20mg/dx4d q 4 wks—10% required a 50% dose reduction of Thalidomide by 2nd cycle of DTPACE
Dex 40qd x 4d
Thal 400 qhs
Cisplatin 10mg/m2/d x 4d
Doxorubicin 10mg/m2/d x 4d
Cyclophosphamide 400 mg/m2/d x 4d
Etoposide 40mg/m2/d x 4d

60 yr (31-84)
64% M
Previously treated
63% progressive disease after chemo
Light chain=2%

DTPACE cycle #1:
DTPACE cycle #2: 229

Overall Response (≥25%)=73%

m protein reduction:
   Near CR=5%

Overall Response (≥25%)=86%

m protein reduction:
   Near Cr=9%

Extensive toxicity data—cannot determine what is due to thalidomide

Phase II

Alexanian, 2002111

Quality 2/5

Alexanian, 200364


Two papers with the same data

100-300 mg
+ Dex20 mg/m2 x 4d on d1, 9 and 17 q28 days—started 7 mo (4-20) after intensive therapy
Responders maintain Thal 100-150 mg
[treatment > 3 mo; Median f/u not stated]

54 yr (37-61)
71% M

Stable, partial responders after intensive CT and SCT (consolidation therapy after SCT)


Overall Response (≥25%)=81%

m protein reduction:


*Sengar, 2005 (ASCO 6731)112


50 mg
After high dose melphalan+ SCT:
Randomized to maintenance Thal vs. IFN randomized (unclear if phase II or phase III)

70—Unclear if enrollment continuing or goal n
52 yr (26-65)
74% M

Stage III=70%
Other MM characteristics NS

17 randomized


Unblinded data not presented



Median duration of maintenance=14 mo

*Stewart, 2004 (ASH 335)113

200-400 mg
Thalidomide/Prednisone maintenance after ASCT with Melphalan 200 mg/m2:
Prednisone 50 mg qod + Thal 200 vs.400 mg
Randomized Phase II
[36.8 mo]


Pt and MM characteristics NS
Numbers randomized to each arm NS


Overall Response (≥25%)=UTD

m protein reduction:
   post-tx CR or near CR=15%
   @ 1 yr CR + near CR=38%

PFS post-ASCT=32.3 mo

OS @ 1 yr=91%

Primary endpoint=incidence of dose reduction or dropout:
   Thal 200 arm=31%
   Thal 400 arm=64%

Allowing for dose reductions, # on each arm at 18 mo after registration:
   Thal 200 arm=76%
   Thal 400 arm=41%

Because of excessive treatment toxicity enrollment in the 400mg dose arm was closed after completing the first phase of the planned enrollment.

Abbreviations: *=abstract, ASCT=Autologous stem cell transplant, CI=Confidence Intervals, CR=Complete Response, CT=consolidation therapy, DTPACE=combination chemotherapy including Dex/Thal/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide, EFS=event free survival, HDT=high dose therapy, IFN=Interferon, Near CR=+IFE only, NS=not stated, OS=overall survival, pt(s)=patient(s), SCT=stem cell transplant, UTD=unable to determine, VAD=standard chemotherapy including Vincristine/Doxorubicin/Dexamethasone

Return to Document
Proceed to Next Table

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care